Cell distribution differences of matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in patients with Kawasaki disease

Seigo Korematsu; Yoko Ohta; Naotaka Tamai; Masahiro Takeguchi; Chika Goto; Hiroaki Miyahara; Tatsuya Kawano; Tatsuro Izumi

doi:10.1097/INF.0b013e31825ba6b3

Cell distribution differences of matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in patients with Kawasaki disease

Pediatr Infect Dis J. 2012 Sep;31(9):973-4. doi: 10.1097/INF.0b013e31825ba6b3.

Authors

Seigo Korematsu¹, Yoko Ohta, Naotaka Tamai, Masahiro Takeguchi, Chika Goto, Hiroaki Miyahara, Tatsuya Kawano, Tatsuro Izumi

Affiliation

¹ Department of Pediatrics and Child Neurology, Oita University Faculty of Medicine, Hasama, Yufu, Oita, Japan. kseigo@oita-u.ac.jp

PMID: 22895216
DOI: 10.1097/INF.0b013e31825ba6b3

Abstract

The interaction of matrix metalloproteinase (MMP)-9 and tissue inhibitor of matrix metalloproteinase-1 has been implicated in the formation of coronary aneurysms in Kawasaki disease. MMP-9 and tissue inhibitor of matrix metalloproteinase-1 were distributed predominantly in the granulocytes and platelets, respectively, in patients with Kawasaki disease. The plasma values of MMP-9 correlated positively with the circulating neutrophil count. Inhibiting the activity of granulocytes and maintaining the platelet activity might prevent coronary aneurysms.

MeSH terms

Blood Platelets / enzymology
Blood Proteins / chemistry
Case-Control Studies
Child, Preschool
Coronary Aneurysm / enzymology
Female
Humans
Immunoglobulins, Intravenous / therapeutic use
Infant
Leukocyte Count
Leukocytes / enzymology
Male
Matrix Metalloproteinase 9 / blood*
Mucocutaneous Lymph Node Syndrome / drug therapy
Mucocutaneous Lymph Node Syndrome / enzymology*
Tissue Inhibitor of Metalloproteinase-1 / blood*

Substances

Blood Proteins
Immunoglobulins, Intravenous
Tissue Inhibitor of Metalloproteinase-1
Matrix Metalloproteinase 9